

**Distribution Date: May 1, 2020**

The following medical protocol updates include information on protocols that have undergone an annual review over the last several months, or an additional review in order to make changes. The annual review may have resulted in a revision to the guidelines or no changes at all. One new protocol has been added and one has been archived.

Please note that portions of this protocol update may not pertain to the members to whom you provide care.

### **Protocol Revision Summary**

The effective date of these changes is June 1, 2020:

#### **Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies** (formerly Expanded Molecular Panel Testing of Cancers to Identify Targeted Therapies)

Change:

- Language in the investigational policy statement changed from “expanded cancer molecular panels” to “comprehensive genomic profiling.”

Medicare Advantage Change:

- Medically necessary criteria expanded to include any cancer diagnosis.

#### **Dermatologic Applications of Photodynamic Therapy**

Changes:

- Additional medically necessary criteria added for photodynamic therapy.
- A not medically necessary statement added.

#### **General Approach to Genetic Testing**

Change:

- A medically necessary statement for chimerism analysis was added.

#### **Intensity-Modulated Radiotherapy: Abdomen and Pelvis**

Change:

- One medically necessary statement modified to include cancer of rectal locations.

#### **Intensity-Modulated Radiotherapy: Central Nervous System Tumors**

Change:

- Removed statement in protocol that states “This protocol does not address radiation treatment for metastasis to the brain or spine.”

#### **Intracavitary Balloon Catheter Brain Brachytherapy for Malignant Gliomas**

Changes:

- An additional investigational policy statement addressing brain mets added.
- Removed the statement “Note: This protocol policy statement does not address metastasis to the brain.”

**Measurement of Serum Antibodies to Selected Biologic Agents** (formerly Measurement of Serum Antibodies to Infliximab and Adalimumab)

Changes:

- The investigational policy statement reworded to include newer tumor necrosis factor (TNF) blocking agents.
- Statement added in Policy Guideline section listing currently FDA-approved TNF blocking agents.

**Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer**

Change:

- BRAF variant added to a medically necessary policy statement.

**Novel Biomarkers in Risk Assessment and Management of Hyperlipidemia in Cardiovascular Disease** (formerly Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease)

Change:

- “Hyperlipidemia in” added to the investigational policy statement.

**Panniculectomy, Abdominoplasty, and Excision of Redundant Skin** (formerly Panniculectomy and Abdominoplasty)

Changes:

- Criteria for one medically necessary statement modified.
- One not medically necessary statement added.
- Policy guidelines revised and references added.

**New Protocols**

The effective date of these new protocols is June 1, 2020:

**Intensity-Modulated Radiotherapy of the Breast and Lung**

- There are medically necessary, not medically necessary and investigational policy statements.
- Preauthorization is not required.

**Intensity-Modulated Radiotherapy of the Prostate**

- There are medically necessary and investigational policy statements.
- Preauthorization is not required.

**Protocols Reviewed Without Change**

Previous effective dates indicated remain accurate for the following:

- Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms
- Amniotic Membrane and Amniotic Fluid
- Antigen Leukocyte Antibody Test
- Automated Ambulatory Blood Pressure Monitoring for Diagnosis of Hypertension in Patients With Elevated Office Blood Pressure
- Bioengineered Skin and Soft Tissue Substitutes
- Biofeedback as a Treatment of Fecal Incontinence or Constipation
- Bioimpedance Devices for Detection and Management of Lymphedema

- Cochlear Implant
- Computed Tomography Perfusion Imaging of the Brain
- Confocal Laser Endomicroscopy
- Cosmetic vs. Reconstructive Surgery or Services
- Cytochrome P450 Genotype-Guided Treatment Strategy
- Diagnosis and Treatment of Sacroiliac Joint Pain
- Dynamic Spinal Visualization and Vertebral Motion Analysis
- Electrostimulation and Electromagnetic Therapy for Treating Wounds
- Gender Reassignment Surgery
- Genetic Testing for Alzheimer Disease
- Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy
- Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia
- Hyperbaric Oxygen Therapy
- Intensity-Modulated Radiotherapy: Cancer of the Head and Neck or Thyroid
- Isolated Small Bowel Transplant
- Kidney Transplant
- Light Therapy for Psoriasis
- Liver Transplant and Combined Liver-Kidney Transplant
- Lung and Lobar Lung Transplant
- Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders
- Nerve Graft With Radical Prostatectomy
- Outpatient Pulmonary Rehabilitation
- Percutaneous Electrical Nerve Stimulation and Percutaneous Neuromodulation Therapy
- Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
- Pharmacogenetic Testing for Pain Management
- Placental and Umbilical Cord Blood as a Source of Stem Cells
- Plugs for Anal Fistula Repair
- Stereotactic Radiosurgery and Stereotactic Body Radiotherapy
- Transanal Radiofrequency Treatment of Fecal Incontinence
- Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
- Vertebral Axial Decompression
- Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders

### Deleted Protocol

Effective immediately, the following protocol is archived:

- Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

**The above are brief summaries.** Please refer to the protocols posted on our provider website for the details and new protocols that affect your practice. If you need help finding a specific protocol update, please contact the Provider Service department.